Skip to main content

Table 1 Comparison of clinical features between LUAD patients with low and high ESCO2 levels in TCGA database

From: ESCO2 promotes lung adenocarcinoma progression by regulating hnRNPA1 acetylation

Clinical character# Clinical
groups
ESCO2 x2 p value
High
(n = 155) (%)
-Low
(n = 155) (%)
Age (years) ≤ 60 54 (34.8) 41 (26.5) 2.611 0.106
>  60 95 (61.3) 108 (69.7)
Gender*** Male 91 (58.7) 59 (38.1) 13.23 < 0.001
Female 64 (41.3) 96 (61.9)
ALK Translocation No 54 (34.8) 71 (45.8) 0.377 0.539
Yes 12 (7.7) 12 (7.7)
pT status*** T1 T2 ~ T4 37 (23.9) 66 (42.6) 12.27 < 0.001
117 (75.5) 88 (56.8)
pN status** N0 88 (56.8) 110 (71.0) 8.771 0.003
N1 ~ N2 66 (42.6) 40 (25.8)
pM status* M0 106 (68.4) 101 (65.2) 4.026 0.045
M1 13 (8.4) 4 (2.6)
Recurred/Progressed** No 62 (40.0) 88 (56.8) 8.317 0.004
Yes 67 (43.2) 46 (29.7)
Clinical Stage** Stage I ~ IIA 83 (53.5) 106 (68.4) 7.761 0.005
Stage IIB ~ IV 70 (45.2) 46 (29.7)
  1. Differences with *p<0.05, **p<0.01 or ***p<0.001 were considered statistically significant
  2. #American Joint Committee on Cancer classification (Version 7) (AJCC)